CureVac N.V.
CVAC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $535,180 | $53,758 | $67,420 | $102,990 |
| % Growth | 895.5% | -20.3% | -34.5% | – |
| Cost of Goods Sold | $105,829 | $124,366 | $183,993 | $238,195 |
| Gross Profit | $429,351 | -$70,608 | -$116,573 | -$135,205 |
| % Margin | 80.2% | -131.3% | -172.9% | -131.3% |
| R&D Expenses | $153,034 | $115,724 | $62,550 | $815,907 |
| G&A Expenses | $69,651 | $76,009 | $88,994 | $87,201 |
| SG&A Expenses | $74,335 | $76,433 | $89,411 | $88,944 |
| Sales & Mktg Exp. | $4,447 | $424 | $417 | $1,743 |
| Other Operating Expenses | $24,300 | $11,442 | -$17,682 | -$627,793 |
| Operating Expenses | $251,669 | $203,599 | $134,279 | $277,058 |
| Operating Income | $177,682 | -$274,207 | -$249,457 | -$412,263 |
| % Margin | 33.2% | -510.1% | -370% | -400.3% |
| Other Income/Exp. Net | $13,199 | $14,238 | $302 | -$235 |
| Pre-Tax Income | $190,881 | -$259,969 | -$249,155 | -$412,498 |
| Tax Expense | $28,695 | $198 | -$126 | -$782 |
| Net Income | $162,186 | -$260,167 | -$249,029 | -$411,716 |
| % Margin | 30.3% | -484% | -369.4% | -399.8% |
| EPS | 0.72 | -1.18 | -1.32 | -2.21 |
| % Growth | 161% | 10.6% | 40.3% | – |
| EPS Diluted | 0.72 | -1.18 | -1.32 | -2.21 |
| Weighted Avg Shares Out | 224,377 | 220,481 | 189,075 | 186,013 |
| Weighted Avg Shares Out Dil | 225,270 | 220,833 | 189,075 | 186,013 |
| Supplemental Information | – | – | – | – |
| Interest Income | $12,357 | $16,731 | $4,009 | $10,103 |
| Interest Expense | $0 | $2,493 | $3,707 | $10,338 |
| Depreciation & Amortization | $18,809 | $23,386 | $26,161 | $35,878 |
| EBITDA | $209,690 | -$234,090 | -$209,386 | -$386,486 |
| % Margin | 39.2% | -435.5% | -310.6% | -375.3% |